# Roche lung cancer drug reduced risk of recurrence, death in late-stage trial
**FDA Update**

**2023-10-18 06:19**

**https://www.ainvest.com/news/roche-lung-cancer-drug-reduced-risk-of-recurrence-death-in-late-stage-trial-2310100057569a88d7c34c14/**

Roche Holding's Alecensa drug reduced the risk of disease recurrence or death in a phase 3 trial for a type of non-small cell lung cancer at an early stage, the company said Wednesday.